Safety profile of acoramidis in cardiac amyloidosis: insights from post-marketing pharmacovigilance data

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mrs Joyce Gu

Erie (United States of America)

6 More presentations in this session

Presentation thumbnail

Vutrisiran-mediated knockdown of transthyretin in patients with transthyretin amyloidosis

Doctor V. Algalarrondo (Paris, FR)

Abstract Slides Video

Presentation thumbnail

CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results

Doctor Y. Razvi (London, GB)

Abstract Slides Video

Presentation thumbnail

Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study

Doctor T. Damy (Creteil, FR)

Abstract Slides Video

Presentation thumbnail

A trial emulation study comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy using calibration and indirect treatment comparison methods: the ReplicATTR Study

Doctor P. Zwetsloot (Rotterdam, NL)

Abstract Slides Video

Presentation thumbnail

Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis

Doctor A. Abovich (Boston, US)

Abstract Slides Video

Access the full session

Session thumbnail

Transthyretin amyloidosis: long-term outcomes and emerging therapies

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Therapeutic advances in amyloid cardiomyopathy

Congress Session

Transthyretin amyloidosis: long-term outcomes and emerging therapies

Congress Session

The evolving landscape of transthyretin amyloidosis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources